No annual revenue total was found in Disc Medicine, Inc.'s SEC filings.
Disc Medicine, Inc. (IRON) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$181.3 million. As of Jun 30, 2026 it held $717.7 million in cash and investments and $60.9 million in total debt.
Revenue
—
Net income (TTM)
$-245.89M
-69.1% vs year-ago TTM
Operating cash flow (TTM)
$-197.54M
-47.2% vs year-ago TTM
Free cash flow (TTM)
$-197.58M
-45.8% vs year-ago TTM
EPS (TTM)
$-6.56
-44.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
38.16M
+10.4% vs prior year
Net cash
$656.88M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRON (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Watertown, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1816736
- Former names
- Gemini Therapeutics, Inc. /DE (until Dec 28, 2022); FS Development Corp. (until Feb 8, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$236.0M | -$129.7M | -$91.1M | -$47.5M | -$30.9M |
| Net income | -$212.2M | -$109.4M | -$76.4M | -$46.8M | -$36.0M |
| Diluted EPS | -$6.01 | -$3.96 | -$3.42 | -$45.05 | — |
| Operating cash flow | -$180.4M | -$93.9M | -$73.5M | -$42.3M | -$27.5M |
| Free cash flow | -$181.3M | -$94.4M | -$73.6M | -$42.4M | -$27.6M |
| Total assets | $806.9M | $496.8M | $368.0M | $200.2M | $92.4M |
| Total liabilities | $67.1M | $53.2M | $22.9M | $23.6M | $14.8M |
| Stockholders' equity | $739.8M | $443.6M | $345.1M | $176.6M | -$64.2M |
| Cash and investments | $791.2M | $489.9M | $360.4M | $194.6M | $88.0M |
| Total debt | $30.7M | $30.0M | $2.1M | $1.3M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Oct 22, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 30, 2026 | Jun 25, 2026 |
All 775 Disc Medicine, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.